Literature DB >> 3567848

Prognostic factor in neuroblastoma.

A E Evans, G J D'Angio, K Propert, J Anderson, H W Hann.   

Abstract

Known prognostic factors in neuroblastoma were analyzed in 124 children to determine which were independent and which were most useful in predicting outcome. The following factors were analyzed: age, sex, stage of disease, serum neuron-specific enolase (NSE), serum ferritin, E-rosette inhibition, urinary catecholamines, and histologic type according to the criteria of Shimada. Estimates of survival were calculated using the method of Kaplan and Meier. The overall survival for 124 patients was 60% at 2 years. There were significant differences in survival by pathology, age, NSE, ferritin, vanilmandelic acid (VMA): homovanillic acid (HVA) ratio, and stage. There was a strong association among NSE, age, stage, and ferritin. Using the recursive partitioning approach, it was possible to subdivide patients into three groups (based on diagnostic values of ferritin, age, and stage) with a good, intermediate, and poor prognosis and estimated 2-year survival of 100%, 62%, and 19%, respectively. Further analysis could not be done because of small numbers in the subgroups, but the results suggest that combinations of age, stage, serum ferritin, and histologic type may be able to define two populations: favorable with 80% + 2-year survival and unfavorable with less than 20%.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3567848     DOI: 10.1002/1097-0142(19870601)59:11<1853::aid-cncr2820591102>3.0.co;2-f

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  44 in total

1.  Regarding some aspects of the positive and negative effects of ionizing and medical treatment of pediatric brain tumors.

Authors:  P Iannetti; L A Basile; L Chessa
Journal:  Childs Nerv Syst       Date:  1992-10       Impact factor: 1.475

2.  Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.

Authors:  Rie Suganuma; Larry L Wang; Hideki Sano; Arlene Naranjo; Wendy B London; Robert C Seeger; Michael D Hogarty; Julie M Gastier-Foster; A Thomas Look; Julie R Park; John M Maris; Susan L Cohn; Gabriele Amann; Klaus Beiske; Catherine J Cullinane; Emanuele S G d'Amore; Claudio Gambini; Jason A Jarzembowski; Vijay V Joshi; Samuel Navarro; Michel Peuchmaur; Hiroyuki Shimada
Journal:  Pediatr Blood Cancer       Date:  2012-06-28       Impact factor: 3.167

3.  Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry.

Authors:  Octavio Burgues; Samuel Navarro; Rosa Noguera; Antonio Pellín; Amparo Ruiz; Victoria Castel; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2006-08-29       Impact factor: 4.064

4.  Screening for neuroblastoma in the north of England.

Authors:  L Parker; A W Craft; G Dale; S Bell; M Cole; A C McGill; J A Seviour; J Smith
Journal:  BMJ       Date:  1992-11-21

5.  Assessment of fine needle aspiration cytology samples for molecular genetic analysis in neuroblastoma.

Authors:  Ankur Mandelia; Sandeep Agarwala; Arundhati Sharma; Venkateswaran K Iyer; Veereshwar Bhatnagar
Journal:  Pediatr Surg Int       Date:  2013-11       Impact factor: 1.827

6.  Histological features of primary tumors after induction or high-dose chemotherapy in high-risk neuroblastoma.

Authors:  Tomoro Hishiki; Hiroshi Horie; Yasuyuki Higashimoto; Katsumi Yotsumoto; Shugo Komatsu; Yuri Okimoto; Harumi Kakuda; Yuichi Taneyama; Takeshi Saito; Keita Terui; Tetsuya Mitsunaga; Mitsuyuki Nakata; Hidemasa Ochiai; Moeko Hino; Kumiko Ando; Hideo Yoshida; Jun Iwai
Journal:  Pediatr Surg Int       Date:  2014-07-27       Impact factor: 1.827

7.  Prognostic importance of DNA flow cytometrical, histopathological and immunohistochemical parameters in neuroblastomas.

Authors:  N L Carlsen; K Ornvold; I J Christensen; H Laursen; J K Larsen
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

8.  Malignant phenotype correlating with drug resistance in two human neuroblastoma cell lines.

Authors:  Y Wollman; I Shahar; M Goldstein; J Leibovici
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

9.  Midkine is highly expressed in neuroblastoma tissues.

Authors:  Henning C Fiegel; Jussuf T Kaifi; Robin Wachowiak; Alexander Quaas; Kuniaki Aridome; Keiko Ichihara-Tanaka; Takashi Muramatsu; Roman Metzger; Jakob R Izbicki; Rudolf Erttmann; Dietrich Kluth; Holger Till
Journal:  Pediatr Surg Int       Date:  2008-12       Impact factor: 1.827

10.  Lack of Thy1 (CD90) expression in neuroblastomas is correlated with impaired survival.

Authors:  Henning C Fiegel; Jussuf T Kaifi; Alexander Quaas; Emine Varol; Annika Krickhahn; Roman Metzger; Guido Sauter; Holger Till; Jakob R Izbicki; Rudolf Erttmann; Dietrich Kluth
Journal:  Pediatr Surg Int       Date:  2008-01       Impact factor: 1.827

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.